Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 285
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
The Problems We Will Be Lucky to Have
Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date
Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It
Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona
Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine
Field Trip Health Ltd. Announces Opening of Psychedelic-Enhanced Therapy Center in...
Psyched Wellness Signs Supply Agreement for Amanita Muscaria
Tryp Therapeutics Partners with Fluence for Psychotherapy Design
Mydecine Reports Full Year 2020 Financial Results and Provides Business Update
Champignon Brands Changes Name to Braxia Scientific to Reflect the Integration...
Psychedelic Bulletin: MindMed Uplists to Nasdaq; Cybin Targets Alcoholism; COMPASS Announces...
Ketanserin’s Contributions to Psychedelic Research
Should Society Legalize Psychedelics? A Breakdown of the Intelligence Squared Debate
PTSF57 – New Compounds, Psychedelic Business, and Neurogenesis
COMPASS Pathways announces pricing of public offering
Load more